Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
2.120
+0.050 (2.42%)
Apr 24, 2025, 4:00 PM EDT - Market closed

Company Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States.

The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies.

It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins.

Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc.
Compass Therapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Thomas Schuetz

Contact Details

Address:
80 Guest Street, Suite 601
Boston, Massachusetts 02135
United States
Phone 617 500 8099
Website compasstherapeutics.com

Stock Details

Ticker Symbol CMPX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001738021
CUSIP Number 20454B104
ISIN Number US20454B1044
SIC Code 2836

Key Executives

Name Position
Dr. Thomas J. Schuetz M.D., Ph.D. Chief Executive Officer
Vered Bisker-Leib MBA, Ph.D. Advisor
Barry Shin J.D. Chief Financial Officer
Neil L. Lerner CPA Senior Vice President and Chief Accounting Officer
Jonathan Anderman J.D. Senior Vice President, General Counsel and Corporate Secretary
Anna Gifford Communications Manager
Dr. Minori Rosales M.D., Ph.D. Senior Vice President and Head of Clinical Development
Karin Herrera B.A. Senior Vice President and Head of Clinical Operations
Dr. James Kranz Ph.D. Vice President and Head of Chemistry Manufacturing and Controls

Latest SEC Filings

Date Type Title
Apr 11, 2025 SCHEDULE 13D/A Filing
Apr 9, 2025 144 Filing
Apr 9, 2025 144 Filing
Apr 1, 2025 8-K Current Report
Mar 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 4, 2025 SCHEDULE 13G Filing